Evidence map›Paper›PMID 34175896›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021

Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.

Tim Hansum, Eva Hollemans, Esther I Verhoef, Chris H Bangma, John Rietbergen, Susanne Osanto, Rob C M Pelger, Tom van Wezel, Henk van der Poel, Elise Bekers and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Tim Hansum *Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. t.hansum@erasmusmc.nl.ORCID 0000-0002-4413-5623
Eva Hollemans *Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-2406-5370
Esther I VerhoefDepartment of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-2734-0254
Chris H BangmaDepartment of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
John RietbergenDepartment of Urology, Franciscus Gasthuis & Vlietland Hospital, Rotterdam, The Netherlands.
Susanne OsantoDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Rob C M PelgerDepartment of Urology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-6328-6462
Tom van WezelDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-5773-7730
Henk van der PoelDepartment of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Elise BekersDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jozien HellemanDepartment of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Sebastiaan RemmersDepartment of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Geert J L H van LeendersDepartment of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-2176-9102
Erasmus MC · NLLeiden University Medical Center · NLThe Netherlands Cancer Institute · NLSint Franciscus Gasthuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Individual growth patterns and cribriform architecture are increasingly considered in risk stratification and clinical decision-making in men with prostate cancer. Our objective was to establish the prognostic value of individual Gleason 5 patterns in a radical prostatectomy (RP) cohort. We reviewed 1064 RPs and recorded Grade Group (GG), pT-stage, surgical margin status, Gleason 4 and 5 growth patterns as well as intraductal carcinoma. The clinical endpoints were biochemical recurrence and post-operative distant metastasis. Gleason pattern 5 was present in 339 (31.9%) RPs, of which 47 (4.4%) presented as primary, 166 (15.6%) as secondary, and 126 (11.8%) as tertiary pattern. Single cells/cords were present in 321 (94.7%) tumors with Gleason pattern 5, solid fields in 90 (26.5%), and comedonecrosis in invasive carcinoma in 32 (9.4%) tumors. Solid fields demonstrated either a small nested morphology (n = 50, 14.7%) or medium to large solid fields (n = 61, 18.0%). Cribriform architecture was present in 568 (53.4%) RPs. Medium to large solid fields and comedonecrosis coincided with cribriform architecture in all specimens, and were not observed in cribriform-negative cases. In multivariable analysis adjusted for Prostate-Specific Antigen, pT-stage, GG, surgical margin status and lymph node metastases, cribriform architecture (Hazard Ratio (HR) 9.9; 95% Confidence Interval (CI) 3.9-25.5, P < 0.001) and comedonecrosis (HR 2.1, 95% CI 1.2-3.7, P = 0.01) were independent predictors for metastasis-free survival, while single cells/cords (HR 1.2; 95% CI 0.7-1.8, P = 0.55) and medium to large solid fields (HR 1.6, 95% CI 0.9-2.7, P = 0.09) were not. In conclusion, comedonecrosis in invasive carcinoma is an independent prognostic Gleason 5 pattern for metastasis-free survival after RP. These data support the current recommendations to routinely include cribriform pattern in pathology reports and indicate that comedonecrosis should also be commented on.

Indexed as

ProstatectomyAdenocarcinomaAgedCarcinoma, Intraductal, NoninfiltratingDisease-Free SurvivalFollow-Up StudiesHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsProstate-Specific AntigenProstate-Specific Antigen

Identifiers

PMID34175896
PMCPMC8514328
OpenAlexW3174634163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.